Skip to main content
. 2018 Jan 30;38(1):BSR20171357. doi: 10.1042/BSR20171357

Figure 3. Illustration of immunotherapeutic response in TNBC.

Figure 3

PD-1 and CTLA-4 are immune checkpoints that prevent immune response towards cancer cells. PD-1 immune checkpoint inhibitors like Permbrolizumab; Durvalumab; Azetolimumab and CTLA-4 inhibitors like Ipilimumab; Tremelimumab inhibit checkpoints and take the ‘brakes off’ T cells thereby activating immune response to attack cancer cells. IMMU-132 is an antibody–drug conjugate delivering topoisomerase I inhibitor (SN-38) targeting Trop-2 receptors on cancer cells.